In a significant move to preserve continuity of care for millions of Americans, federal health and drug enforcement agencies have once again prolonged the flexible telehealth prescribing rules for controlled substances that originated during the public health emergency. This joint action by the
In a landmark decision that promises to reshape the landscape of cancer treatment technology in India, the Central Drugs Standard Control Organization (CDSCO) has brought much-needed clarity to a previously ambiguous regulatory environment by finalizing a comprehensive risk-classification list for
The persistent stream of personal health data that once trickled from our wrists has swelled into a sophisticated symphony of actionable intelligence, a clear theme that resonated through the halls of the Consumer Electronics Show this year. The event marked a significant maturation point for the
The U.S. Food and Drug Administration has dramatically reshaped the future of personal health technology by rolling out significant updates to its regulatory framework for consumer wearables and artificial intelligence-powered software. Announced by FDA Commissioner Marty Makary, M.D., during the
The biopharmaceutical sector is holding its collective breath as a series of high-stakes regulatory decisions promises to redraw competitive maps and dictate market leadership for years to come. The first quarter is not just another period of clinical trial readouts and earnings reports; it
In a significant move poised to reshape the digital health landscape, the U.S. Food and Drug Administration has officially recalibrated its approach to regulatory oversight for a rapidly expanding category of consumer technology. The agency recently issued new guidance that effectively limits its
